Elan Shares Plunged: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Despite beating Wall Street's estimates for first-quarter results, shares of Elan (NYSE: ELN  ) plunged as much as 15% in early trading today. The stock has since recovered to be down about 4%.

So what: Elan earned $0.12 per diluted share on $313 million in Q1. Analysts had been calling for a $0.03 loss on $297.04 million, according to Yahoo! Finance data.

Now what: It didn't matter. Biogen Idec (Nasdaq: BIIB  ) , an Elan partner in marketing the MS drug Tysabri, reported promising trial results for a competing MS treatment called BG-12. (Click here to read about Biogen's stock pop.) If approved, the new drug could cut into Elan's Tysabri sales because it's administered orally rather than intravenously. Tysabri patients are also regularly screened for a rare brain disease called PML, which can manifest as a side effect.

Investors' fears of Tysabri, which accounted for 78% of Elan's first-quarter revenue, being replaced may be justified someday. For now, it's important to remember that Elan easily beat estimates while Biogen's BG-12 remains in a phase 3 trial. Mr. Market is likely overreacting. 

Interested in more info on Elan? Add it to your watchlist.

Interested in more info on Biogen Idec? Add it to your watchlist.

Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team. Elan is a Rule Breakers recommendation. You can try any of our Foolish newsletter services free for 30 days.

Tim didn't own shares in any of the companies mentioned in this article at the time of publication. Check out his portfolio holdings and Foolish writings, or connect with him on Twitter as @milehighfool. You can also get his insights delivered directly to your RSS reader. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is also on Twitter as @TheMotleyFool. Its disclosure policy is at least 10% better than other disclosure policies.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 21, 2011, at 7:10 PM, JesseJamesFinn wrote:

    What do you make of QCOR's MS drug?

  • Report this Comment On April 22, 2011, at 6:02 AM, jimmoy wrote:

    What you need to know is that Elan is a dreadfully managed company that, at least since 2004, has consistently disappointed its investors, sometimes in a spectacular fashion.

    The fact that it did slightly better than analysts expectations is nothing for them to be proud of. Expenses are huge and the pipeline is virtually empty.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1479699, ~/Articles/ArticleHandler.aspx, 10/30/2014 10:44:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement